July 23, 2013 08:00 AM Eastern Daylight Time
BERKELEY, Calif. -- Aduro BioTech, Inc. announces today the appointment of Gregory W. Schafer as chief operating officer (COO). As COO, Mr. Schafer will lead the company’s corporate strategy and operations.
“We are delighted to bring Greg into Aduro at this exciting time as we move into later-stage clinical trials with our lead program for pancreatic cancer,” said Stephen Isaacs, chairman and chief executive officer of Aduro. “We look forward to leveraging Greg’s extensive experience in the industry, particularly as it relates to planning and supporting the growing and more complex operations of a biotechnology company progressing towards commercialization.”
Mr. Schafer brings more than 23 years of broad operational, financial and strategic leadership expertise to Aduro and has raised over $650 million in public and private transactions to fund biotechnology product development and commercialization activities. Most recently, he served as chief financial officer of Jennerex, Inc. for 3 years, where he was responsible for finance, accounting, planning, investor relations and treasury functions. Prior to Jennerex, he served as chief financial officer of Onyx Pharmaceuticals, Inc., where he was responsible for finance, accounting, risk management and strategic and operational planning. Before joining Onyx, he served as chief financial officer and vice president of finance for Cerus Corporation, where he worked together with then-chief executive officer Stephen Isaacs to transition the company from early-stage development to product approval. Prior to Cerus, Mr. Schafer worked as a management consultant for Deloitte & Touche, LLP and as an engineer specializing in biologics manufacturing. Mr. Schafer also serves on the board of directors for Nile Therapeutics, a public biotechnology company. He received his MBA from the Anderson Graduate School of Management at the University of California, Los Angeles and a BSE in mechanical engineering from the University of Pennsylvania.
About Aduro BioTech, Inc.
Aduro BioTech, Inc. is a clinical-stage immunotherapy company located in Berkeley, California. Aduro has completed enrollment in a randomized, controlled Phase 2 clinical trial in patients with metastatic pancreatic cancer and is conducting a Phase 1B trial in patients with malignant pleural mesothelioma. In addition, the company’s preclinical pipeline includes programs in glioblastoma, prostate cancer, melanoma, malaria, HBV and tularemia.
Aduro BioTech, Inc.
Steven Bodovitz, Ph.D.